Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-03-07 M&A Activity
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
Other material contracts - English.pdf
M&A Activity Classification · 100% confidence The document is titled 'ASSET PURCHASE AGREEMENT' and contains detailed legal and transactional language regarding the sale and purchase of intellectual property assets between parties. It references loan agreements, court orders, bankruptcy proceedings, and specific terms related to the transfer of assets. There is no indication that this is a financial report, earnings release, regulatory filing, or any other type of corporate disclosure report. Instead, it is a legal agreement related to a transaction. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids, including asset purchase agreements.
2024-03-07 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer details, distribution dates, purchaser information, types of securities distributed, compensation related to the distribution, and information about directors and officers. The form is a regulatory filing related to exempt distributions of securities, which is a specific compliance report rather than a financial report like an annual or quarterly report. It does not contain financial statements or management discussion and analysis. The document is lengthy (15,000 characters) and contains detailed regulatory disclosure information. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-03-06 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, types of securities distributed, purchaser information, compensation paid in connection with the distribution, and jurisdictional breakdowns. The form is a regulatory filing related to exempt distributions under Canadian securities law, specifically referencing National Instrument 45-106. It is not a financial report like an annual or interim report, nor is it an earnings release or management discussion. It is a formal regulatory filing reporting on exempt securities distributions and related compensation. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-03-06 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, types of securities distributed, purchaser information, compensation paid in connection with the distribution, and jurisdictional breakdowns. The form is a regulatory filing used in Canada to report exempt distributions of securities. It is not an annual report, earnings release, or any other financial report type but a specific regulatory filing related to securities distribution compliance. The document is lengthy (15,000 characters) and contains substantive data, not merely an announcement or certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other categories.
2024-03-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the allowance of a patent in Japan and the filing of additional international patent applications by BioVaxys Technology Corp. It discusses intellectual property developments and patent filings but does not contain any financial statements, management discussion, or regulatory certifications. There is no indication that this is a financial report, earnings release, or regulatory filing. It is a corporate announcement related to intellectual property and patent status. Such announcements do not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-03-05 English
Report of exempt distribution (45-106F1) (amended).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about securities distribution, including issuer details, distribution dates, purchaser information, compensation related to the distribution, and regulatory compliance data. It is a regulatory filing form used to report exempt distributions of securities, which is a compliance and disclosure document rather than a financial report or earnings release. The document does not contain financial statements, management discussion, or audit information. It is a regulatory compliance filing specific to securities distribution under Canadian securities law. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-02-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.